前立腺肥大症に対するセルニルトン錠の臨床的検討

Abstract

Gueyonの病期分類1期, 2期の前立腺肥大症22例に対してセルニルトン(R)錠を投与した.1)自覚症状に対する改善率は非常に良く, 排尿困難の各症状については85%以上の改善率がえられた.全般的自覚症状改善率は22例中, 中等度改善率以上が18例(81.8%), 軽度改善が2例(9.1%)不変2例(9.1%), 悪化0例であった.2)他覚的所見では排尿量測定, 残尿量などで3例に改善例がみられたが, 直腸診, 逆行性尿道・膀胱造影, 経直腸的超音波断層法などでは前立腺の縮小変化が認められなかった.3)副作用は全例になんらみられなかった

Twenty-two patients whose average age was 67 years and who had benign prostatic hyperplasia of stage I and II were treated with Cernilton for more than 4 weeks. Subjective symptoms were excellently improved and the improvement rate was over 85% in all of the evaluated symptoms of dysuria. In the overall evaluation, 18 out of 22 patients were rated as moderately improved or better, 2 were slightly improved and 2 remained unaltered. Aggravation of the symptoms was found in none of the patients. Objective findings such as residual urine volume and urinary flow rate were improved in 3 patients, although the shrinkage of the prostate was not observed on rectal palpation, retrograde urethro cystography or transrectal ultrasonography. No adverse reaction was observed during Cernilton therapy. In conclusion, it is suggested that Cernilton may be effective and safe for the conservative treatment of patients with early stage prostatic hyperplasia of non-surgical indication.